mRNA vaccine for cancer immunotherapy

Abstract

mRNA vaccines have become a promising platform for cancer immunotherapy. During vaccination, naked or vehicle loaded mRNA vaccines efficiently express tumor antigens in antigen-presenting cells (APCs), facilitate APC activation and innate/adaptive immune stimulation. mRNA cancer vaccine precedes other conventional vaccine platforms due to high potency, safe administration, rapid development potentials, and cost-effective manufacturing. However, mRNA vaccine applications have been limited by instability, innate immunogenicity, and inefficient in vivo delivery. Appropriate mRNA structure modifications (i.e., codon optimizations, nucleotide modifications, self-amplifying mRNAs, etc.) and formulation methods (i.e., lipid nanoparticles (LNPs), polymers, peptides, etc.) have been investigated to overcome these issues. Tuning the administration routes and co-delivery of multiple mRNA vaccines with other immunotherapeutic agents (e.g., checkpoint inhibitors) have further boosted the host anti-tumor immunity and increased the likelihood of tumor cell eradication. With the recent U.S. Food and Drug Administration (FDA) approvals of LNP-loaded mRNA vaccines for the prevention of COVID-19 and the promising therapeutic outcomes of mRNA cancer vaccines achieved in several clinical trials against multiple aggressive solid tumors, we envision the rapid advancing of mRNA vaccines for cancer immunotherapy in the near future. This review provides a detailed overview of the recent progress and existing challenges of mRNA cancer vaccines and future considerations of applying mRNA vaccine for cancer immunotherapies.

Cited by papers we hold 19

• Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy · 2024
  No notice
• Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications · 2024
  No notice
• Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions · 2024
  No notice
• Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics · 2023
  No notice
• CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances · 2023
  No notice
• Nanomaterials in tumor immunotherapy: new strategies and challenges · 2023
  No notice
• Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review · 2023
  No notice
• Targeting ferroptosis opens new avenues for the development of novel therapeutics · 2023
  No notice
• mRNA vaccines in disease prevention and treatment · 2023
  No notice
• mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy · 2022
  Not checked
• A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies · 2022
  No notice
• mRNA as a Therapeutics: Understanding mRNA Vaccines · 2022
  Not checked
• Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies · 2022
  No notice
• Cancer vaccines as promising immuno-therapeutics: platforms and current progress · 2022
  No notice
• Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging · 2022
  No notice
• mRNA vaccines for cancer immunotherapy · 2022
  No notice
• RNA-based therapeutics: an overview and prospectus · 2022
  No notice
• Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines · 2021
  No notice
• Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.